Oramed Pharmaceuticals Inc.
ORMP· Nasdaq
ORMPOramed Pharmaceuticals Inc.
Filed Mar 6, 2024 · 10-K · 66 days after period end · 0001213900-24-020485
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures |
|---|---|---|---|---|
| Revenue | $0.00 | $681.00K | $681.00K | $617.00K |
| Net Income | $12.90M | -$8.26M | -$17.83M | -$2.93M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
ended Dec 31, 2023 · filed Mar 6, 2024 · 66 d after period end
